<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971161</url>
  </required_header>
  <id_info>
    <org_study_id>allo-APZ2-CVU-IIb</org_study_id>
    <nct_id>NCT04971161</nct_id>
  </id_info>
  <brief_title>Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-blind, Dose-Ranging, Multicenter, Phase IIb Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Chronic Venous Ulcer (CVU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RHEACELL GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FGK Clinical Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ticeba GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RHEACELL GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size&#xD;
      reduction of CVUs) and safety (by monitoring adverse events [AEs]) of three dose groups of&#xD;
      the investigational medicinal product (IMP) allo-APZ2-CVU, topically administered on target&#xD;
      wounds of patients with CVU compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, double-blind, dose-ranging, multicenter, phase IIb&#xD;
      clinical trial to investigate the efficacy and safety of the IMP allo-APZ2-CVU on wound&#xD;
      healing in patients with therapy-resistant CVU. The allogeneic IMP allo-APZ2-CVU contains&#xD;
      skin-derived ABCB5-positive dermal mesenchymal stromal cells isolated from skin tissue of&#xD;
      healthy donors and stored in a donor cell bank.&#xD;
&#xD;
      Patients will be randomized to be treated with allo-APZ2-CVU (dose 1, dose 2, dose 3) or&#xD;
      placebo (50 patients per dose group). The patients will undergo treatment with the IMP on Day&#xD;
      0 (V3) and will be followed up for efficacy for 18 weeks (V4 until V14). Two safety follow-up&#xD;
      visits will be performed at Month 6 (V15) and Month 10 (V16).&#xD;
&#xD;
      The wound healing process will be documented by standardized photography. The wound size&#xD;
      measurement will start at the first Screening Visit (V1) and will be measured at each&#xD;
      following on-site visit.&#xD;
&#xD;
      Pain will be assessed using a numerical rating scale and quality of life will be investigated&#xD;
      with standardized and validated questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, double-blind, dose-ranging, interventional, multicenter, phase IIb clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete wound closure at Week 18 already persisting for at least two weeks</measure>
    <time_frame>Week 18</time_frame>
    <description>Complete wound closure at Week 18 already persisting for at least two weeks will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse event (AE) occurrence</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>All AEs occurring during the clinical trial will be registered, documented and evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound size change in percent at each post-baseline follow-up visit</measure>
    <time_frame>Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10</time_frame>
    <description>Wound size change in percent at each post-baseline follow-up visit will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete wound closure</measure>
    <time_frame>Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10</time_frame>
    <description>Time to complete wound closure will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete wound closures at each post-baseline follow-up visit</measure>
    <time_frame>Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10</time_frame>
    <description>Complete wound closures at each post-baseline follow-up visit will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of wound closure</measure>
    <time_frame>Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10</time_frame>
    <description>Duration of wound closure will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of the wound</measure>
    <time_frame>Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10</time_frame>
    <description>Recurrence of the wound will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of wound healing (wound exudate) at each post-baseline follow-up visit</measure>
    <time_frame>Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10</time_frame>
    <description>The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the amount and type of wound exudate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of wound healing (granulation tissue together with epithelialization) at each post-baseline follow-up visit</measure>
    <time_frame>Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10</time_frame>
    <description>The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the formation of granulation tissue together with epithelialization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of wound healing (scar formation) at each post-baseline follow-up visit</measure>
    <time_frame>Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10</time_frame>
    <description>The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the questions regarding scar formation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14</measure>
    <time_frame>Week 6, 12, 18</time_frame>
    <description>Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14 will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit</measure>
    <time_frame>Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10</time_frame>
    <description>Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination and vital signs at V14</measure>
    <time_frame>Week 18</time_frame>
    <description>A physical body examination (e.g. general appearance, thyroid, head, lungs and thorax, ears, cardiovascular system, eyes, abdomen, nose-mouth-throat, musculoskeletal system, skin, extremities, lymph nodes, neurological system) will be performed and abnormal physical examination results will be evaluated and reported as AEs.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Skin Ulcer Venous Stasis Chronic</condition>
  <arm_group>
    <arm_group_label>allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm²)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of IMP on patients wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Application of IMP on patients wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm²)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of IMP on patients wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm²)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of IMP on patients wound</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allo-APZ2-CVU</intervention_name>
    <description>Suspension of ABCB5-positive dermal mesenchymal stromal cells. One topical application with a syringe.</description>
    <arm_group_label>allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm²)</arm_group_label>
    <arm_group_label>allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm²)</arm_group_label>
    <arm_group_label>allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm²)</arm_group_label>
    <other_name>Skin-derived ABCB5-positive dermal mesenchymal stromal cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One topical application with a syringe</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients at least 18 years old;&#xD;
&#xD;
          2. Chronic venous leg ulcer (as defined by the current AWMF guidelines: therapy-resistant&#xD;
             ulcer that shows no tendency to heal within 3 months despite of optimal phlebological&#xD;
             therapies or has not fully healed within 12 months) at lower leg and/or ankle region&#xD;
             and has not been present longer than 15 years, diagnosed by doppler or duplex&#xD;
             sonography, ankle brachial index (ABI, 0.9-1.3), physical examination and&#xD;
             dermatological review;&#xD;
&#xD;
          3. Wound size of target ulcer between 1 and 50 cm² measured by a standardized photography&#xD;
             at the screening visits (Visit 1 and Visit 2);&#xD;
&#xD;
          4. If patients have 2 or more ulcers at the same extremity, the target ulcer has to be&#xD;
             separated by a minimum bridge of 1 cm of epithelialized skin from other ulcers (the&#xD;
             largest ulcer should be the target ulcer, if not decided otherwise at discretion of&#xD;
             the investigator; the target ulcer is defined at Visit 1);&#xD;
&#xD;
          5. Body mass index between 15 and 50 kg/m²;&#xD;
&#xD;
          6. Patients understand the nature of the procedure and are providing written informed&#xD;
             consent prior to any clinical trial procedure;&#xD;
&#xD;
          7. Women of childbearing potential must have a negative blood pregnancy test at Visit 1;&#xD;
&#xD;
          8. Women of childbearing potential and their partner must be willing to use highly&#xD;
             effective contraceptive methods during the course of the clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of the ulcer extending to the underlying muscle, tendon, or bone;&#xD;
&#xD;
          2. Diabetes mellitus that has to be confirmed by blood test (Hemoglobin A1c &gt;7.5%);&#xD;
&#xD;
          3. Peripheral Artery Disease including claudication with need of treatment;&#xD;
&#xD;
          4. Acute deep vein thrombosis (maximum 30 days from diagnosis) or a still untreated deep&#xD;
             vein thrombosis;&#xD;
&#xD;
          5. Unable to tolerate leg ulcer compression bandage;&#xD;
&#xD;
          6. Infection of the target ulcer requiring treatment as judged clinically;&#xD;
&#xD;
          7. All diagnosed disorders, unrelated to CVU, that are influencing wound healing of the&#xD;
             target wound at investigator's discretion;&#xD;
&#xD;
          8. Current use of medications that influence wound healing: systemic immunosuppressives,&#xD;
             cytotoxic medicinal products, and systemic steroids (above Cushing-threshold level);&#xD;
&#xD;
          9. Patient who, in the opinion of the investigator, for any reason are unable or&#xD;
             unwilling to complete the trial per protocol (e.g. alcohol or substance abuse, not&#xD;
             mobile, short life expectancy) or there is evidence of any other medical condition&#xD;
             (such as psychiatric illness, physical examination, or laboratory findings) that may&#xD;
             interfere with the planned treatment, affect the patient's compliance, or place the&#xD;
             patient at high risk of complications related to the treatment;&#xD;
&#xD;
         10. Any malignancy within the past 5 years, excluding successfully treated carcinoma in&#xD;
             situ, basal cell carcinoma or squamous cell carcinoma of the skin without evidence of&#xD;
             metastases;&#xD;
&#xD;
         11. Pregnant or lactating women;&#xD;
&#xD;
         12. Any known allergies to components of the IMP;&#xD;
&#xD;
         13. Prior surgical procedures such as bypass or mesh-graft treatment at target leg within&#xD;
             2 months prior to Visit 1 at target leg;&#xD;
&#xD;
         14. Patients with significant ulcer healing or wound size enlargement of more than 25% at&#xD;
             Visit 2 compared to Visit 1;&#xD;
&#xD;
         15. Treatment of target ulcer with active wound care agents (e.g. Iruxol®N), which have&#xD;
             not been paused 14 days before IMP application;&#xD;
&#xD;
         16. Current or previous (within 30 days of enrollment) treatment with another IMP, or&#xD;
             participation and/or under follow-up in another clinical trial;&#xD;
&#xD;
         17. Previous participation in this clinical trial (except for screening failures due to an&#xD;
             inclusion or exclusion criterion);&#xD;
&#xD;
         18. Employees of the sponsor, or employees or relatives of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Kerstan, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Würzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Ganss, Dr.</last_name>
    <phone>+49 6221 71833</phone>
    <phone_ext>0</phone_ext>
    <email>office@rheacell.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Mößmer</last_name>
    <phone>+49 6221 71833</phone>
    <phone_ext>0</phone_ext>
    <email>anna.moessmer@rheacell.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Augsburg, Klinik für Dermatologie und Allergologie, Campus Süd</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Welzel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fachklinik Bad Bentheim, Dermatologische Ambulanz</name>
      <address>
        <city>Bad Bentheim</city>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athanasios Tsianakas, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franziskus-Krankenhaus Berlin, Klinik für Innere Medizin, Angiologie und Diabetologie</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berthold Amann, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hautärzte Braunschweig am Altstadtmarkt, Hautärztliche Gemeinschaftspraxis</name>
      <address>
        <city>Braunschweig</city>
        <zip>38100</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herms Wittstock, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum &quot;Carl Gustav Carus&quot; der Technischen Universität Dresden, Medizinische Klinik und Poliklinik III Angiologie und Gefäßzentrum</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Weiss, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Klinik für Dermatologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman-Philipp Hoff, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Hautklinik - Wundzentrum Dermatologie</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Erfurt-Berge, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Klinik für Dermatologie und Venerologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dimitra Kiritsi, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienhospital Gelsenkirchen GmbH, Klinik für Chirurgie (Allgemein-, Viszeral- und Endokrine Chirurgie, Thorax-, Gefäß- und Endovaskuläre Chirurgie und Kinderchirurgie)</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45886</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mansur Duran, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera GmbH, Zentrum für Klinische Studien</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Sell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Abdou Zarzour</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdou Zarzour, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg- Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Augustin, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Prof. Dr. Ockenfels, Haut und Allergie-Praxisklinik GmbH</name>
      <address>
        <city>Hanau</city>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Michael Ockenfels, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SRH Klinikum Karlsbad- Langensteinbach GmbH, Interdisziplinäres Gefäßzentrum Innere Medizin</name>
      <address>
        <city>Karlsbad</city>
        <zip>76307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwin Blessing, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum DermaKiel GmbH</name>
      <address>
        <city>Kiel</city>
        <zip>24148</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Brüning, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Krefeld, Klinik für Dermatologie und Venerologie</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Horn, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Langenau, Studienzentrum</name>
      <address>
        <city>Langenau</city>
        <zip>89129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beate Schwarz, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>medamed GmbH, Studienambulanz Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Schubert, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beldio Research GmbH</name>
      <address>
        <city>Memmingen</city>
        <zip>87700</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Schwinn, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermazentrum München, Standort Neuhausen, Studienzentrum</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Bönisch, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Görge, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord, Klinik für Dermatologie</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erwin S. Schultz, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Prof. Dr. med. Khusru Asadullah</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khusru Asadullah, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caritas-Krankenhaus St. Josef, Klinik für Plastische und Ästhetische, Hand- und Wiederherstellungschirurgie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Seitz, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock, Klinik und Poliklinik für Dermatologie und Venerologie</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susen Rode</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken Schwerin, Plastische, Rekonstruktive und Ästhetische Chirurgie</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Masberg, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hautärztliche Gemeinschaftspraxis Dr. Leitz und Kollegen</name>
      <address>
        <city>Stuttgart</city>
        <zip>70178</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Leitz, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Universitäts-Hautklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anke Strölin, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik für Dermatologie und Allergologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christiane Pfeiffer, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Universitätsklinikum Wuppertal, Zentrums für Dermatologie, Allergologie und Dermatochirurgie</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silke Carolin Hofmann, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Kerstan, PD Dr. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Venous Ulcer</keyword>
  <keyword>ABCB5</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Dermal mesenchymal stromal cells</keyword>
  <keyword>varicose ulcer</keyword>
  <keyword>skin ulcer</keyword>
  <keyword>advanced therapy medicinal product</keyword>
  <keyword>somatic cell therapy</keyword>
  <keyword>phase IIb</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Skin Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

